多西他赛腹腔灌注加静脉化疗联合阿帕替尼治疗胃癌腹膜转移的疗效及安全性  

The Efficacy and Safety of Docetaxel Peritoneal Perfusion plus Intravenous Chemotherapy and Apatinib in the Treatment of Peritoneal Metastasis of Gastric Cancer

作　　者：董祥宁[1] 蒋宗惠[1] 陈晨 王维飞[1] DONG Xiangning;JIANG Zonghui;CHEN Chen;WANG Weifei(Department of Oncology,The First Chuzhou People’s Hospital,Chuzhou,Anhui,239000;Department of Medical Ultrasonics,The First Chuzhou People’s Hospital,Chuzhou,Anhui,239000)

机构地区：[1]滁州市第一人民医院肿瘤内科,安徽滁州239000 [2]滁州市第一人民医院超声科,安徽滁州239000

出　　处：《肿瘤药学》2020年第6期741-744,749,共5页Anti-Tumor Pharmacy

摘　　要：目的探究多西他赛腹腔灌注加静脉化疗联合阿帕替尼治疗胃癌腹膜转移的疗效及安全性。方法选取2015年4月—2018年4月我院收治的50例胃癌腹膜转移患者,以抽签的方式分为观察组与对照组,各25例。对照组患者采用多西他赛腹腔灌注加静脉化疗;观察组在对照组的基础上联合阿帕替尼进行治疗。观察并比较两组患者的临床疗效、治疗2个周期后的血清肿瘤标志物水平变化、化疗副反应以及1、2、3年生存率。结果观察组癌胚抗原(CEA)、糖类抗原125(CA125)、CA19-9水平均显著低于对照组(P<0.05),治疗总有效率显著高于对照组(P<0.05);观察组不良反应发生率为52.00%,对照组为32.00%,但差异无统计学意义(P>0.05);观察组患者1、2、3年生存率均高于对照组,但差异无统计学意义(P>0.05)。结论多西他赛腹腔灌注加静脉化疗联合阿帕替尼治疗胃癌腹膜转移效果显著,可显著降低机体肿瘤标志物水平,能有效控制与缓解临床症状,延长患者生存期。Objective To explore the efficacy and safety of docetaxel peritoneal perfusion combined with intravenous chemotherapy plus apatinib in the treatment of peritoneal metastasis of gastric cancer.Methods Fifty patients with gastric cancer peritoneal metastasis who were admitted to our hospital between April 2015 and April 2018 were selected and divided into control group and observation group by lottery,with 25 patients in each group.Patients in the control group were treated with docetaxel peritoneal perfusion plus intravenous chemotherapy.Patients in the observation group were treated with docetaxel peritoneal perfusion plus intravenous chemotherapy combined with apatinib tablets.The clinical effects were compared between the two groups.The levels of serum tumor markers and chemotherapeutic side effects were observed after two cycles of treatment.The 1-,2-and 3-year survival rates were also observed and compared.Results The levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),and carbohydrate antigen 19-9(CA19-9)in the observation group were significantly lower than those of the control group(P<0.05).The total effective rate in the observation group was significantly higher than in the control group(P<0.05).The incidence of adverse reactions in the observation group was 52.00%,higher than 32.00%in the control group,but there was no statistical difference between the two groups(P>0.05).The 1-,2-and 3-year survival rates of the observation group were all higher than those of the control group,but with no statistical significance(P>0.05).Conclusion Docetaxel peritoneal perfusion plus intravenous chemotherapy combined with apatinib had a good curative effect in the treatment of peritoneal metastasis of gastric cancer.It could effectively alleviate the clinical symptoms,control the disease and extend the survival of patients.

关 键 词：多西他赛 阿帕替尼 胃癌腹膜转移 

分 类 号：R735.2[医药卫生—肿瘤]